Foundry Healthcare Inventory Discipline Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1UNH | UNITEDHEALTH GROUP INC | Healthcare | $386.95B | 24.56% |
2AMGN | AMGEN INC | Healthcare | $197.69B | 12.55% |
3DHR | DANAHER CORP | Healthcare | $144.26B | 9.16% |
4PFE | PFIZER INC | Healthcare | $142.77B | 9.06% |
5HCA | HCA HEALTHCARE INC | Healthcare | $82.34B | 5.23% |
6CI | CIGNA GROUP | Healthcare | $74.45B | 4.73% |
7REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $70.94B | 4.50% |
8IDXX | IDEXX LABORATORIES INC | Healthcare | $44.76B | 2.84% |
9BDX | BECTON DICKINSON & CO | Healthcare | $43.58B | 2.77% |
10TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Healthcare | $37.30B | 2.37% |
11VEEV | VEEVA SYSTEMS INC | Healthcare | $31.74B | 2.01% |
12BIIB | BIOGEN INC | Healthcare | $30.41B | 1.93% |
13INCY | INCYTE CORP | Healthcare | $23.42B | 1.49% |
14GH | GUARDANT HEALTH INC | Healthcare | $20.67B | 1.31% |
15VTRS | VIATRIS INC | Healthcare | $20.14B | 1.28% |
16JAZZ | JAZZ PHARMACEUTICALS PLC | Healthcare | $15.53B | 0.99% |
17DVA | DAVITA INC | Healthcare | $15.21B | 0.97% |
18ALGN | ALIGN TECHNOLOGY INC | Healthcare | $12.66B | 0.80% |
19BMRN | BIOMARIN PHARMACEUTICAL INC | Healthcare | $11.52B | 0.73% |
20HALO | HALOZYME THERAPEUTICS INC | Healthcare | $9.23B | 0.59% |
21IONS | IONIS PHARMACEUTICALS INC | Healthcare | $8.99B | 0.57% |
22TGTX | TG THERAPEUTICS INC | Healthcare | $8.40B | 0.53% |
23BIO | BIO-RAD LABORATORIES INC | Healthcare | $8.15B | 0.52% |
24LNTH | LANTHEUS HOLDINGS INC | Healthcare | $7.00B | 0.44% |
25CHE | CHEMED CORP | Healthcare | $6.77B | 0.43% |
26XENE | XENON PHARMACEUTICALS INC | Healthcare | $6.60B | 0.42% |
27LGND | LIGAND PHARMACEUTICALS INC | Healthcare | $6.08B | 0.39% |
28TFX | TELEFLEX INC | Healthcare | $5.96B | 0.38% |
29BLCO | BAUSCH & LOMB CORP | Healthcare | $5.80B | 0.37% |
30TXG | 10X GENOMICS INC | Healthcare | $5.55B | 0.35% |
31TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $5.27B | 0.33% |
32SHC | SOTERA HEALTH CO | Healthcare | $5.06B | 0.32% |
33VCYT | VERACYTE INC | Healthcare | $4.72B | 0.30% |
34VKTX | VIKING THERAPEUTICS INC | Healthcare | $4.31B | 0.27% |
35WAY | WAYSTAR HOLDING CORP | Healthcare | $4.27B | 0.27% |
36HAE | HAEMONETICS CORP | Healthcare | $3.54B | 0.22% |
37WRBY | WARBY PARKER INC | Healthcare | $3.24B | 0.21% |
38GRAL | GRAIL INC | Healthcare | $3.12B | 0.20% |
39VERA | VERA THERAPEUTICS INC | Healthcare | $2.76B | 0.18% |
40ESTA | ESTABLISHMENT LABS HOLDINGS INC | Healthcare | $2.72B | 0.17% |
41NEOG | NEOGEN CORP | Healthcare | $2.24B | 0.14% |
42IOVA | IOVANCE BIOTHERAPEUTICS INC | Healthcare | $2.23B | 0.14% |
43AUPH | AURINIA PHARMACEUTICALS INC | Healthcare | $2.05B | 0.13% |
44HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.96B | 0.12% |
45TYRA | TYRA BIOSCIENCES INC | Healthcare | $1.91B | 0.12% |
46NEO | NEOGENOMICS INC | Healthcare | $1.90B | 0.12% |
47MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $1.87B | 0.12% |
48ZBIO | ZENAS BIOPHARMA INC | Healthcare | $1.86B | 0.12% |
49VRDN | VIRIDIAN THERAPEUTICS INC | Healthcare | $1.86B | 0.12% |
50ZYME | ZYMEWORKS INC | Healthcare | $1.77B | 0.11% |
51HCSG | HEALTHCARE SERVICES GROUP INC | Healthcare | $1.74B | 0.11% |
52BFLY | BUTTERFLY NETWORK INC | Healthcare | $1.73B | 0.11% |
53TDOC | TELADOC HEALTH INC | Healthcare | $1.70B | 0.11% |
54INVA | INNOVIVA INC | Healthcare | $1.60B | 0.10% |
55VIR | VIR BIOTECHNOLOGY INC | Healthcare | $1.59B | 0.10% |
56PRGO | PERRIGO CO PLC | Healthcare | $1.48B | 0.09% |
57ARDT | ARDENT HEALTH INC | Healthcare | $1.46B | 0.09% |
58XNCR | XENCOR INC | Healthcare | $1.30B | 0.08% |
59AZTA | AZENTA INC | Healthcare | $1.21B | 0.08% |
60TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.17B | 0.07% |
61MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $1.15B | 0.07% |
62WVE | WAVE LIFE SCIENCES LTD | Healthcare | $1.12B | 0.07% |
63USPH | U S PHYSICAL THERAPY INC | Healthcare | $1.12B | 0.07% |
64EYPT | EYEPOINT INC | Healthcare | $1.12B | 0.07% |
65BVS | BIOVENTUS INC | Healthcare | $1.01B | 0.06% |
66VOR | VOR BIOPHARMA INC | Healthcare | $980M | 0.06% |
67PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $873M | 0.06% |
68AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $871M | 0.06% |
69AVR | ANTERIS TECHNOLOGIES GLOBAL CORP | Healthcare | $823M | 0.05% |
70ZVRA | ZEVRA THERAPEUTICS INC | Healthcare | $755M | 0.05% |
71TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $648M | 0.04% |
72MYGN | MYRIAD GENETICS INC | Healthcare | $584M | 0.04% |
73WEAV | WEAVE COMMUNICATIONS INC | Healthcare | $575M | 0.04% |
74ANGO | ANGIODYNAMICS INC | Healthcare | $558M | 0.04% |
75ZURA | ZURA BIO LTD | Healthcare | $518M | 0.03% |
76XOMA | XOMA ROYALTY CORP | Healthcare | $504M | 0.03% |
77PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.03% |
78UPB | UPSTREAM BIO INC | Healthcare | $382M | 0.02% |
79ZNTL | ZENTALIS PHARMACEUTICALS INC | Healthcare | $364M | 0.02% |
80ZSQR | Z SQUARED INC | Healthcare | $260M | 0.02% |
81SMTI | SANARA MEDTECH INC | Healthcare | $229M | 0.01% |
82KPTI | KARYOPHARM THERAPEUTICS INC | Healthcare | $216M | 0.01% |
83FOCL | FOCAL INC | Healthcare | $204M | 0.01% |
84AMWL | AMERICAN WELL CORP | Healthcare | $199M | 0.01% |
85TNXP | TONIX PHARMACEUTICALS HOLDING CORP | Healthcare | $198M | 0.01% |
86DERM | JOURNEY MEDICAL CORP | Healthcare | $197M | 0.01% |
87PDEX | PRO DEX INC | Healthcare | $183M | 0.01% |
88INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $180M | 0.01% |
89INGN | INOGEN INC | Healthcare | $178M | 0.01% |
90RCEL | AVITA MEDICAL INC | Healthcare | $157M | 0.01% |
91UNCY | UNICYCIVE THERAPEUTICS INC | Healthcare | $144M | 0.01% |
92VTVT | VTV THERAPEUTICS INC | Healthcare | $130M | 0.01% |
93VRCA | VERRICA PHARMACEUTICALS INC | Healthcare | $96M | 0.01% |
94AGPU | AXE COMPUTE INC | Healthcare | $72M | 0.00% |
95XLO | XILIO THERAPEUTICS INC | Healthcare | $53M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $1.58T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 98% toward Large, 46% toward Growth. +4% unclassified (15 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual64.5%Margin-10.5%No more than 25% of total assets may be invested in the securities of any one issuer.
Required<= 25.0%Actual24.6%Margin0.4%Close to the line. The engine flags this verdict as one a routine data rebuild could flip. Read it as borderline rather than settled — the margin beside it is the whole story.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
1 verdict(s) sit within 1.0pp of their limit and can be flipped by a routine data rebuild; do not headline them, and always show the margin.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 33.5% | -2.2% |
| 3 yearsp.a. | 7.6% | -9.7% |
| 5 yearsp.a. | 3.3% | -4.2% |
| 10 yearsp.a. | 9.9% | -2.5% |
| Since inceptionp.a. | 10.0% | -1.1% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 13.8% | 9.3% |
| 2025 | 15.4% | -15.1% |
| 2024 | -3.9% | -19.0% |
| 2023 | -6.2% | -15.8% |
| 2022 | -3.2% | 26.7% |
| 2021 | 25.0% | -0.2% |
| 2020 | 28.5% | 2.6% |
| 2019 | 20.8% | -4.0% |
| 2018 | 1.0% | -5.1% |
| 2017 | 20.2% | 1.4% |
| 2016 | 0.7% | 5.6% |
| 2015 | 10.0% | -0.3% |
| 2014 | 19.5% | -8.3% |
| 2013 | 34.1% | -18.9% |
| 2012 | 14.8% | 2.4% |
| 2011 | 16.9% | 28.4% |
| 2010 | 10.5% | 0.6% |
| 2009 | 27.0% | 2.0% |
| 2008 | -22.0% | -8.8% |
| 2007 | -2.7% | -11.2% |
| 2006 | 10.2% | 2.3% |
| 2005 | 13.7% | 3.7% |
| 2004 | -0.8% | -2.9% |
| 2003 | 26.1% | -3.9% |
| 2002 | -19.7% | -1.8% |
| 2001 | -7.9% | -2.0% |
| 2000 | 58.4% | -5.2% |
| 1999 | 9.8% | 25.8% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare Inventory Discipline Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Inventory Discipline signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.